The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II clinical studies of UTD1, an epothilone analog, in metastatic breast cancer.
Binghe Xu
No relevant relationships to disclose
Pin Zhang
No relevant relationships to disclose
Zhongsheng Tong
No relevant relationships to disclose
Fuguo Tian
No relevant relationships to disclose
Yongsheng Wang
No relevant relationships to disclose
Jun Lan Yang
No relevant relationships to disclose
Lijun Di
No relevant relationships to disclose
Weilian Li
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Rongguo Qiu
No relevant relationships to disclose
Li Tang
No relevant relationships to disclose